Journal of Psychopharmacology and Therapeutic Advances in Psychopharmacology

Open Access

A large number of new gold open access (OA) journals have been launched in recent years to provide immediate open access to research at the point of publication. It is estimated that 16% of peer reviewed journals are now gold OA. These use funding models that do not charge the reader or institution for access. The most popular funding model is payment by the author of an Article Processing Charge (APC) at the point of acceptance, although there are other models, such as funding by societies or through advertising revenue.

However, the hybrid OA/subscription journal is still the most common way of publishing open access and Journal of Psychopharmacology (JOP) has been publishing gold OA articles since 2011.  Over 10% of articles published in JOP in 2016 were gold OA. The gold OA option at SAGE is called SAGE Choice, and is offered to authors at the production stage so that there can be no implied editorial bias to publish because of a potential payment of APC.

JOP also supports Green Open Access Archiving.  This allows the author to archive the final accepted version of the article immediately on the author’s own personal website, department website or institutional repository. This final accepted version of the author’s manuscript has all the referees’ comments addressed and revisions made, but is the version before the manuscript has entered the SAGE production process. This version cannot be hosted on a subject repository or else that availability would impinge on subscription revenue. The final version is then hosted on the SAGE website. When depositing an accepted version in any repository, credit must be given to the original version in JOP.

The main push towards open access publishing has been from government and funder mandates that argue that the availability of research results to all will speed up the progress of research and that, if the taxpayer has paid for the research, they have the right to see the results. OA, as opposed to Free to View, also requires an open copyright licence of Creative Commons (CC). Some funders require immediate access to the work at the point of publication, which is the Gold Open Access route. However, some funders allow for an embargo of 12 months before the requirement for the final accepted version to be deposited in a subject repository such as PubMed Central. JOP is able to comply with these mandates.

Some argue that it is not fair for a hybrid journal to obtain funding from subscriptions and at the same time to obtain revenue from APCs on some of the articles. This process is sometimes referred to as double dipping. SAGE sees value in this argument and therefore the subscription price of JOP is lowered by the percentage of OA articles that are included in the Journal.

All articles published in Therapeutic Advances in Psychopharmacology (TAP) are free to read and download via the journal website (tpp.sagepub.com) and PubMed Central immediately upon publication. This not only complies with all funder mandates, but facilitates wide access to the latest research, as many clinicians and researchers do not have an institutional access to journals and are not able afford personal subscriptions to journals. Free access is particularly important for clinicians in developing countries. Moreover, free access to articles has been shown to increase citations.

To fund immediate global free access to all articles, TAP charges an article fee that is payable upon acceptance. However, SAGE acknowledges the importance of disseminating the results of research, and the Journal can grant full article fee waivers for authors who are genuinely unable afford publication fees owing to lack of institutional or personal grant funding. Moreover, the Journal supports the Research4Life scheme, meaning that authors from developing countries are usually eligible for article fee discounts or waivers. Authors are encouraged to contact the Managing Editor of the Journal to enquire about these options.

Peer Review

Most journals have been finding it increasingly difficult to find reviewers for new submissions. There is more research and more publications, 5 million submissions with 2.6 million papers published in 2016 up 53% in the last decade.  Although the electronic submission system and keyword databases have made the task of appropriate reviewer selection easier, many researchers just do not have the time required, estimated at about 5 hours, to review a paper. In the past, it was accepted that reviewing content was undertaken within salaried time and that reviewing it helped with advancement within the department. However, with more mobility between institutions, a way of having an authenticated record of contribution to the scientific community by reviewing papers has been developed. This is known as Publons (www.publons.com) and all reviewers are encouraged to register and create their own profile.  JOP and TAP can authenticate a reviewer automatically and, since Publons only publishes the year of the review and the journal title within the reviewer profiles, there is no breach of the Journals’ blinded peer review systems.

JOP and TAP are members of Committee on Publications Ethics (COPE) and the Editor can access direct advice from them on any ethics questions.  SAGE is a publishing member of COPE, and abides by their codes of practice, which require a minimum of 2 independent reviews, and limit the use of suggested reviewers.

Kudos

With 2.5 million articles being published each year, it is important to facilitate the discovery of JOP and TAP articles to maximise visibility, usage and citation.  SAGE has partnered with Kudos (www.growkudos.com), a third party service that allows authors to explain, enrich and share their articles, and then measure the impact of their actions. You can find out more information about how you can engage with this on the SAGE Journal author gateway: https://us.sagepub.com/en-us/nam/journal-author-gateway.

Metrics

The Impact Factor (IF) still reigns supreme and JOP now has an impressive IF of 4.179. As a relatively new journal, TAP does not yet have an official IF; however, using the same citation calculation method as used for the official IF, the Journal has an estimated unofficial IF of  2.901.

The IF is still very important when choosing a journal to publish in, but alternative non citation based metrics are also being used. These differ primarily in that they are article metrics rather than journal metrics, and measure the impact of the research mostly by assessing social media coverage.  The new hosting platform for JOP and TAP allows for increased and immediate measuring of an article’s impact and this is now shown next to the articles online with links to definitions. Clicking on the Altmetric icon within full text view will take you to the full Article Metrics page where you will be given the percentage Attention Score, how many people have tweeted the article and where they are based, and how many Mendeley readers the article has.  Altmetrics also breaks the impact measures down further into types of usage, for example Twitter, blogs, news outlets and policy statements.

For queries relating to Therapeutic Advances in Psychopharmacology, please contact the Managing Editor, Hemi Malkki: Hemi.Malkki@sagepub.co.uk.

For queries relating to Journal of Psychopharmacology, please contact the Publishing Editor, Sophie North: Sophie.North@sagepub.co.uk.

Leave a Reply

Your email address will not be published. Required fields are marked *